Larson Kelsey E, Grobmyer Stephen R, Valente Stephanie A
Division of Breast Services, Department of General Surgery, Cleveland Clinic, Cleveland, OH, USA.
Breast J. 2018 Sep;24(5):749-754. doi: 10.1111/tbj.13041. Epub 2018 Apr 23.
The data on oncologic outcomes in young women with breast cancer (BC) are dated as it relates to recurrences and mortality. Our goal was to assess these outcomes in a modern series of young women with BC. A retrospective chart review identified women ≤40 years old with stage I-III BC diagnosed from 2006 to 2013 at our institution. Demographics, tumor biology, type of operation, recurrence, and survival were analyzed. Overall, 322 women were identified. Most had ER+(70%) infiltrating ductal tumors (88%) with low stage (42% T1; 41% T2; 56% N0). Follow-up was 4.2 years with 5.6% local-regional recurrence (LRR), 15.2% metastatic recurrence (MR), and 8% mortality. There was no survival difference based on demographics, tumor biology, or type of operation. T3 tumors (P < .001) and node positivity (P < .001) were associated with worse disease-free survival. In this modern series of young women with BC, stage rather than tumor biology or surgical choice has more effect on recurrence-free survival. MR was more common than LRR, with most MR occurring within the first 2 years after surgery.
关于年轻乳腺癌（BC）女性肿瘤学结局的数据，就复发和死亡率而言已过时。我们的目标是评估现代年轻BC女性患者的这些结局。一项回顾性病历审查确定了2006年至2013年在我们机构诊断为I - III期BC且年龄≤40岁的女性。分析了人口统计学、肿瘤生物学、手术类型、复发情况和生存率。总体而言，共识别出322名女性。大多数患者为雌激素受体阳性（70%），浸润性导管癌（88%），且分期较低（42%为T1；41%为T2；56%为N0）。随访时间为4.2年，局部区域复发（LRR）率为5.6%，远处转移复发（MR）率为15.2%，死亡率为8%。基于人口统计学、肿瘤生物学或手术类型，生存率无差异。T3肿瘤（P < .001）和淋巴结阳性（P < .001）与无病生存率较差相关。在这个现代年轻BC女性队列中，分期而非肿瘤生物学或手术选择对无复发生存率的影响更大。远处转移复发比局部区域复发更常见，大多数远处转移复发发生在术后的前2年内。
